A wearable wireless system that enables clinicians to evaluate a patient's cardiac health status, wherever in the world they are, has gained CE Mark approval for marketing in the EU.

The Avivo Mobile Patient Management System from Corventis, Inc. is a noninvasive solution to evaluate physiological changes and monitor signs of cardiac irregularities in patients outside the hospital.

The system provides insight into the cardiac health status of patients, such as those suffering from heart failure, by combining a wearable sensor with advanced algorithms, global wireless capability and a web-based infrastructure.

Physiological trends including heart rate, respiratory rate, fluid status, activity and posture are captured and automatically transmitted for review. Any irregularity in the patient's cardiac rhythm triggers an automatic alert.

"Corventis is advancing healthcare worldwide, and the CE Mark for the Avivo Mobile Patient Management System is one additional milestone in our efforts to deliver on this promise," said Ed Manicka, PhD, President and CEO of Corventis. "With both FDA clearance and CE marking, we are able to bring the future of wireless cardiovascular medicine to even more physicians and their patients around the world."

The Avivo system features the PiiX wearable sensor, which enables continuous monitoring for ambulatory patients during normal daily activity. The sensor automatically collects physiological information and transmits it for analysis and presentation on a secure website. With no leads or wires, the patient-friendly design of PiiX encourages continuous wear.

For more details, visit www.corventis.com.